Company Overview
Inovio Pharmaceuticals, Inc. operates as a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines designed to treat and protect individuals from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The company functions within the Healthcare sector, specifically the Biotechnology industry, positioning itself to leverage advancements in genetic medicine for therapeutic applications. Its operational scale is defined by a market capitalization of $111.24M, annual revenue of $65,343, and a workforce of 112 employees. These valuation and revenue figures indicate that the company is a micro-cap entity with minimal current revenue generation relative to its market value, suggesting a stage focused on research and development rather than mature commercial profitability.
Financial Health
The company reported revenue of $65,343 for the trailing twelve months, yet recorded a net income of $-84,945,904 and an EBITDA of $-85,404,192, revealing a severe disconnect between top-line revenue and bottom-line profitability. This significant gap indicates a cost structure where expenses vastly outweigh the minimal revenue, a common characteristic in early-stage biotechnology firms but one that currently precludes operational sustainability. Free cash flow stands at $-38,681,548, which signifies that the company is burning through cash reserves to fund its operations and research initiatives rather than generating liquidity. Regarding profitability metrics, the gross margin is 0.0%, the operating margin is -132871.3%, and the profit margin is 0.0%, collectively indicating that the company has not yet achieved a sustainable profit model where revenue covers variable and fixed costs. On the balance sheet, the company holds $58.51M in cash against $9.37M in debt, resulting in a debt-to-equity ratio of 38.88, which presents a leveraged profile where liabilities are substantial relative to shareholder equity. Despite the high debt-to-equity ratio, the current ratio of 1.40 suggests that the company maintains sufficient short-term assets to cover its short-term liabilities, providing a baseline level of liquidity. However, the return on equity of -183.5% and the return on assets of -57.9% reveal that management is currently destroying shareholder value and utilizing assets inefficiently in the pursuit of future product milestones.
Valuation Assessment
Valuation multiples for Inovio Pharmaceuticals reflect its lack of profitability, as the P/E Ratio (TTM) is N/A and the Forward P/E is -2.49, implying that traditional earnings-based valuation methods are not applicable given the negative earnings trajectory. The price-to-book ratio stands at 4.61, indicating that the market is pricing the company at a significant premium over its book value, likely driven by the potential future value of its DNA medicine platform rather than current financial performance. Alternative valuation metrics such as the price-to-sales ratio of 1702.37 and an EV/EBITDA of -0.73 suggest that the stock price is heavily decoupled from current sales and earnings, relying entirely on speculative expectations of future commercialization. The stock trades within a 52-week range defined by a high of $2.98 and a low of $1.30, meaning the current price sits at a level that reflects high volatility and significant distance from the yearly peak. With a beta of 1.76, the stock exhibits price volatility that is more than 76% higher than the broader market, highlighting the speculative risk associated with investing in this biotechnology asset.
Growth & Income
The company experienced a revenue growth rate of -100.0% year-over-year, while earnings growth is N/A, indicating that the business is in a contraction phase or has reset its revenue base entirely. Since the earnings growth metric is not available due to the lack of profitable earnings, the company is not growing earnings faster than revenue but rather is unable to generate earnings from its current revenue stream. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute income to shareholders and instead reinvests its limited resources, though currently insufficiently, into research and development. The overall growth and income profile is characterized by negative revenue momentum, zero dividend distribution, and a complete absence of profitability, underscoring the high-risk nature of the investment which relies entirely on the successful commercialization of future DNA medicines to alter its financial trajectory.